GE HealthCare reports $1.36 diluted EPS and plans to acquire SOFIE Biosciences
On October 28, 2026, GE HealthCare reported third-quarter financial results, posting diluted earnings per share (EPS) of $1.36 and quarterly revenue of $5,513 million. Simultaneously, the company announced plans to acquire SOFIE Biosciences for $945 million in cash and leadership changes at the Patient Care Solutions division.
Quarterly financial results
In the third quarter of 2026, the company generated $5,513 million in revenue, up 7.2% from the same period last year. Net income attributable to GE HealthCare was $615 million, an increase of 37.9%. Meanwhile, direct tariffs negatively impacted operating income by $53 million for the quarter, although the company received $55 million in tariff refunds.
Quarter vs the same quarter a year earlier
Revenue by quarter, $B
Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.
Leadership changes and strategic plans
The company announced a planned acquisition of SOFIE Biosciences for $945 million in cash. Additionally, there will be a leadership change at the Patient Care Solutions division: Jeannette Bankes will leave her role as president and CEO of the division on November 15, 2026, and Neal Sandy will replace her on November 16, 2026.
Previously, on September 22, 2026, the company announced the appointment of Pascal Desroches to the board of directors, effective January 4, 2027.
Original sources
- 8-K filing, October 28, 2026
- 8-K EX-99 filing, October 28, 2026
- financial data (XBRL)
- 10-Q filing, October 28, 2026
- 8-K EX-99 filing, September 22, 2026
- 8-K filing, September 22, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow GE HealthCare Technologies
A notification in your browser or on your phone when we publish about GE HealthCare Technologies. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
